Adamas Pharmaceuticals, Forest Laboratories deal

Adamas said it received $40 million in milestones from Forest under a 2012 deal to develop and commercialize Adamas' memantine ER/donepezil ( MDX-8704) in the U.S. to treat moderate to severe Alzheimer's disease. Adamas said the milestones were triggered by the completion of studies to support an NDA, which Forest expects to submit to FDA this half. Under the deal, Forest is responsible for regulatory activities and has exclusive U.S. commercialization rights to the product. Adamas is eligible to receive up to $95 million in milestones, plus royalties beginning five years after the launch of the fixed-dose combination. The partners could not be reached for details (see BioCentury, Nov. 19, 2012). ...